Patients with severe COVID-19 had significantly lower levels of the active thyroid hormone fT3 than those with milder illness, suggesting a link between how sick someone is and their thyroid hormone levels. This finding is from the abstract summary - full study details were not available.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review could determine whether low fT3 is a consistent predictor of severity across diverse populations and settings in acute infections.
A systematic review and meta-analysis of all prospective studies measuring fT3 at admission in hospitalized patients with acute respiratory infections, including at least 5,000 participants, stratifying by infection type (COVID-19, influenza, bacterial pneumonia) and adjusting for inflammatory markers.
An RCT could test whether restoring fT3 levels in severe COVID-19 alters clinical outcomes, establishing a causal role.
A double-blind, placebo-controlled trial of 400 hospitalized COVID-19 patients with fT3 below 2.0 pg/mL, randomized to receive intravenous liothyronine (5 mcg/day) vs. placebo for 5 days, with primary outcome being time to discharge or improvement in SOFA score.
A prospective cohort could confirm whether fT3 levels at admission independently predict disease progression after adjusting for confounders.
A multicenter prospective cohort of 800 hospitalized adults with confirmed COVID-19, measuring fT3, TSH, and CRP at admission and daily for 7 days, with severity defined by WHO ordinal scale, adjusting for age, sex, BMI, and inflammatory markers.
A case-control study could compare fT3 levels between severe and mild cases to identify a threshold predictive of severity.
A matched case-control study comparing 250 severe (ICU) and 250 mild (ward) COVID-19 patients, matched for age, sex, and comorbidities, measuring admission fT3, TSH, and CRP to determine optimal predictive cutoff.
A cross-sectional study could describe the distribution of fT3 levels in a single cohort of hospitalized patients with varying severity.
A single-timepoint survey of 600 hospitalized COVID-19 patients measuring fT3 at admission and classifying severity by oxygen requirement, to estimate median levels and crude association.